In an open‐label, phase 1b clinical trial (NCT02523469), the combination of ALT‐803 with PD‐1 monoclonal antibodies (mAb) was assessed for safety and efficacy in NSCLC patients. Here, PDCD1 is linked to non-small cell lung carcinoma.